Advaxis is actively seeking commercialization partners for the license and development of its proprietary investigational Lm Technology immunotherapies.

Advaxis has created more than 20 distinct immunotherapy candidates based on its proprietary platform that are available for partnering in anti-PD-1 combination therapy, recurrent cervical cancer, HPV-associated head and neck cancer, HPV-associated anal cancer, prostate cancer, HER2 expressing tumors, and others.

Interested parties may contact:

Ranya Dajani
Vice President, Business Development
Advaxis, Inc.
305 College Rd East
Princeton, NJ 0854